NCT05161702 - Increased Inflammation-resolving Activity by Omega-3 Monoglycerides in Peripheral Blood Mononuclear Cells (PBMC). | Biotech Hunter

Enrollment

200

Participants

Timeline

Start Date

March 12, 2019

Primary Completion Date

December 31, 2025

Study Completion Date

January 1, 2026

Conditions

Resolution of InflammationReduction of Cell Proliferation

Interventions

OTHER

MAG-SPM treatment on isolated PBMC cells

Cells are isolated form the participant's blood donation (4x 10mL k2EDTA tubes per participant) and maintained in culture with LPS, a pro-inflammatory and pro-proliferative agent. Then, PBMC are separated in two, one half treated with MAG-SPM and the other half remains with LPS only. Proliferative activities are measured and compared in both cell dish.

OTHER

Isolated PBMC cells without treatment.

Cells are isolated form the participant's blood donation (4x 10mL k2EDTA tubes per participant) and maintained in culture with LPS, a pro-inflammatory and pro-proliferative agent. Then, PBMC are separated in two, one half treated with MAG-SPM and the other half remains with LPS only. Proliferative activities are measured and compared in both cell dish.

Trial Locations (1)

G0K 1P0

RECRUITING

SCF Pharma, Rimouski